Neupogen

This page contains recent news articles, when available, and an overview of Neupogen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Neupogen

市场:生物仿制?规模低于预期  -  23 Nov 2009
中国化工网...在生物制?产?中,将会?到仿制?挑战的有安进公?的化疗?物Neupogen——该产?刺激白血?的生?,以?基因泰克公?的Rituxan——用于治疗类风湿性关节炎和??奇金? ...

Teva Launches TevaGrastim (filgrastim)  -  ‎Nov 18, 2009‎
Pharmacy EuropeTevaGrastim is licensed for the same indications as the reference product, Neupogen (filgrastim). Teva's pre-filled syringe will also incorporate a needle ...

PRIMECAP Management Top Holdings: Amgen Inc., Eli Lilly and Company, Novartis ...  -  ‎Nov 22, 2009‎
GuruFocus.comIts principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). ...

Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone  -  ‎Nov 6, 2009‎
BNET...its own “bio-similar? version of Amgen's branded granulocyte colony-stimulating factor, called Neupogen (filgrastim), to EU member states. ...

Is Amgen retreat a case of investor overreaction?  -  ‎Nov 5, 2009‎
Middle East North Africa Financial NetworkAt the same time, sales of Neulasta and Neupogen -- two other leading revenue drivers -- have remained solid but have generally seen only single-digit ...

永昕新藥發展?報頻傳  -  ‎Nov 18, 2009‎
中時電子報...未來GranNEX將進?國際主?市場,上市後在??足以與進?產?Neupogen/Kirin相抗衡,?低我國??支出??國外的?賴。我國GCSF市場?年約3億?幣,GranNEX將為國內第 ...

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial ...  -  07 Aug 2009
FOXBusinessThroughout his 20 years at Amgen, Mike held various positions including Product Development Team Leader for Neupogen as well as Vice President and General

Amgen Second-Quarter Profit Gains on Arthritis Drug  -  ‎Jul 27, 2009‎
BloombergCombined worldwide sales of Neulasta and Neupogen, treatments used to fight infections in patients undergoing chemotherapy, fell 4 percent to $1.16 billion.

Amgen (NASDAQ: AMGN): Second Quarter Earnings Preview 2009  -  ‎Jul 23, 2009‎
istockAnalyst.com (press release)Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively

Our health care isn't 'universal'  -  ‎Jul 29, 2009‎
Toronto SunAnother key to her survival, says Ron, is a drug called Neupogen, prescribed to help boost white blood cell counts and fight infection.

InNexus Biotechnology Announces Business Development Initiative ...  -  ‎Aug 5, 2009‎
FOXBusinessJ&J/Centocor's Remicade(R), Pfizer's Lyrica(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and

Analysts: Amgen most at risk from biogenerics  -  ‎Jul 17, 2009‎
FiercePharmaAnalysts think its blockbuster blood-cell boosters Epogen and Neupogen will be among the first drugs copied in the US, once lawmakers create a framework for

Finding Key To Cancer Drug Gleevec's Limitations  -  ‎Aug 5, 2009‎
Science Daily (press release)Imatinib is being combined either with interferon, rapamycin (also known as sirolimus), arsenic or GM-CSF (marketed as Neupogen).

Thalidomide Doesn't Benefit Patients with Small Cell Lung Cancer ...  -  ‎Jul 24, 2009‎
Cancer ConsultantsPatients received prophylactic Neupogen® (filgrastim) with each course of chemotherapy. If patients achieved an anticancer response to PCDE, they were then

Costly Drugs Known as Biologics Prompt Exclusivity Debate  -  ‎Jul 22, 2009‎
New York TimesThere are plenty of blockbuster biologics, like Epogen and Neupogen from Amgen, that have been on the market more than 12 or 14 years and thus would get no

Zarzio? (filgrastim) now available in the UK for the treatment of ...  -  ‎Jul 21, 2009‎
PharmiWeb.com (press release)Zarzio® has been shown to have an efficacy and safety profile comparable with Neupogen®2, currently the most widely prescribed treatment, but Zarzio is 10%

BUYINS.NET: (AMGN) SqueezeTrigger Price is $62.925. There is ...  -  ‎Aug 4, 2009‎
Trading Markets (press release)Neulasta and NEUPOGEN stimulate the production of neutrophils, one type of white blood cell that helps the body fight infections. ENBREL blocks the biologic

7 Reasons Not to Worry This Week  -  ‎Jul 27, 2009‎
Motley FoolAmgen is the biotech giant that has already caught lightning in a bottle with blockbuster drugs Epogen and Neupogen. It appears to have another winner in

BUYINS.NET: AMGN, RKT, ACV, HXL, CW, PFWD Expected To Be Higher ...  -  ‎Jul 22, 2009‎
Trading Markets (press release)Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively

BUYINS.NET: AMGN, KO, HES, UNP, MT, ECL Expected To Be Higher ...  -  ‎Jul 15, 2009‎
Trading Markets (press release)Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively

Amgen Inc. - SWOT Analysis - new market report just published  -  ‎Jul 24, 2009‎
PR-Inside.com (Pressemitteilung)The increase was primarily due to Enbrel and Neulasta /Neupogen sales growth. The operating profit of the company was $5214 million during FY2008,

Wednesday Newspaper Review - Irish Business News and International ...  -  ‎Jul 22, 2009‎
FinFacts IrelandThere are plenty of blockbuster biologics, like Epogen and Neupogen from Amgen, that have been on the market more than 12 or 14 years and thus would get no

Halozyme Therapeutics Appoints Jonathan Leff, MD as Vice President ...  -  ‎Jul 27, 2009‎
FOXBusiness8 marketed products, and 4 late stage pipeline products, which involved the support and growth of 5 blockbuster brands: Neupogen(TM), Neulasta(TM),

安進公?第二季度淨利潤年增40%至12.7億美元  -  ‎Jul 27, 2009‎
鉅亨網...接?化療患者用以防止感染的Neulasta和Neupogen藥物的??銷售下跌3.6%。 ?責?明:本文所載資料僅供?考,並?構?投資建議,世?財訊?該資料或使用該資料所導致的

安进公?第二季度净利润年增40%至12.7亿美元  -  ‎Jul 27, 2009‎
财讯...上周,惠?表示,Enbrel的国际销售攀?了6%,至7.36亿美元。 接?化疗患者用以防止感染的Neulasta和Neupogen?物的??销售下跌3.6%。

«Amgen» ?ообщает об увеличении прибыли во II кв. 2009 г.  -  ‎Jul 29, 2009‎
Аптека onlineОбщий объем продаж препаратов Neulasta ® /?еула?тим ® (пегфильгра?тим) и Neupogen ® /?ейпоген ® (филгра?тим) ?о?тавил в ?том квартале 1,2 млрд дол.,

Amgen will Denosumab zusammen mit Glaxo vermarkten  -  ‎Jul 27, 2009‎
FOCUS OnlineDie gemeinsamen Umsätze von "Neulasta" und "Neupogen" fielen um 4% auf 1,16 Mrd USD. Hier hatten die Beobachter mit einem höheren Umsatz von 1,18 Mrd USD

İlaçta vurgun iddiası tekrar ağır cezada!  -  ‎Aug 3, 2009‎
Vatanİstanbul Cumhuriyet Savcısı Nazmi Okumuş tarafından Roche ilaç firmasının ithal ettiği “Neupogen? ve “Kiytrill? isimli ilaçların pahalı bir şekilde Sağlık

Pacientes oncológicos sin remedios en Catriel  -  ‎Jul 19, 2009‎
Rio Negro On Line...pero desde abril, esta familia gestiona y golpea puertas infructuosamente para que el Ministerio de Salud decida reintegrar 15 dosis de Neupogen,

Amgen übertrifft Erwartungen - Aktie steigt nachbörslich  -  ‎Jul 27, 2009‎
BörseGo.dePräparat Neupogen verkauft sich mit einem Umsatz von 327 Millionen Dollar ebenso besser als die von den Analysten prognostizierten 322 Millionen Dollar.

Aktientipp Amgen: Neuer Standard  -  ‎Jul 20, 2009‎
WirtschaftsWocheGut 30 Prozent entfallen auf die bei Immunschwäche verabreichten Medikamente Neulasta/Neupogen, etwa ein Viertel auf den Entzündungshemmer Enbrel.



Background information on Neupogen [When available]

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:
  • Stop or slow the growth of cancer cells.
  • Make it easier for your immune system to destroy, or get rid of, cancer cells.
  • Keep cancer from spreading to other parts of your body.
More from the National Cancer Institute

Search the web for more resources on Neupogen



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy